2003; baxter - Supplements - Haematologica
2003; baxter - Supplements - Haematologica 2003; baxter - Supplements - Haematologica
72E. BerntorpMaterials and MethodsStudy materialThe characteritics of the patients studied arelisted in Table 1. Nine patients with severe hemophiliaB (factor IX:C 300 394 4 >600 105 38 120 466 6 100 227 1 >300 58 1 429 1.69 27 3 29From the fourth day after the onset of treatment,gammaglobulin is given intravenously at dailydoses of 0.4 g/kg body weight for 5 days. Theinhibitor usually reappears after 5-6 days, andthe administration of factor concentrates mustbe intensified. For persistent inhibitors recombinantfactor VIIa (NovoSeven ® , Novo Nordisk) ispreferred for treatment of acute bleeds as acti-Figure 1. The Malmö model for Immune Tolerance Induction.haematologica vol. 88(supplement n. 12):september 2003
IV International Workshop on Immune Tolerance in Hemophilia73Table 2. Malmö Treatment Model. Treatment and results ofITI in patients with severe hemophilia B.Patient No. of ITI Protein A ads Time inhibitor Toleranceattempts included detection to first ITI (y) achieved1 1 Yes 2 Yes2 2 Last ITI 9 Yes, relapseafter 6 months3 1 Yes 24 Yes4 1 Yes 10 Yes5 1 No 46 Yes6 1 No 22 Yes7 3 First ITI 2 No8 2 Last ITI 2 No9 1 No 26 NoTable 3. Malmö Treatment Model. Follow-up of patients withsevere hemophilia B (31 Dec., 2002).PatientFollow-up time (years)1 112 Relapse after 6 months3 19.54 175 Not known6 12.57 Not tolerant8 Not tolerant9 Not tolerantvated prothrombin complex concentrates shouldgive a booster effect in factor IX-deficientpatients. The definition of a tolerant state is asfollows: no measurable inhibitor, normal recoveryand half-life, and efficient prophylaxis withstandard doses, i.e. 25-40 IU/kg body weighttwice a week in hemophilia B. If tolerance isachieved and considered successful, the patientcontinues on ordinary prophylaxis. If tolerance isnot successful, the treatment can be repeatedafter 6-12 months when the inhibitor productionhas leveled out and reached a steady-state.A new attempt at a shorter interval will considerablyjeopardize the possibility of reducing theinhibitor by extracorporeal protein A adsorption,increase the cost of the treatment and probablydecrease the possibility of success.Concentrates usedProthrombin complex concentrate was used infive patients (Preconativ ® , Kabi; Prothromplex ® ,Immuno). Purified factor IX was used in fourpatients (Nanotiv ® , Pharmacia; Mononine ® ,Aventis Behring; Immunine ® , Baxter and Alphanine® , Alpha).ResultsNine patients were treated according to theMalmö protocol using a total of 13 attempts. Insix of the patients only one attempt was made.Protein A adsorption was used in six attempts.Tolerance was achieved in six of the eight highrespondingpatients. One patient relapsed aftersix months. This patient was treated again witha full treatment schedule including protein Aadsorption. A prothrombin complex concentratewas used. Two weeks after the start of treatmentthe patient developed an acute myocardial infarctionand died from heart failure two years later.Other events associated with the ITI includeheadache and one patient also experienced arterialbleeding in connection with puncture of theradial artery and developed a compartment syndrome.The patient recovered. The patients’ follow-upis indicated in Table 3. Thus, four patientshave been in a tolerant state for 10-20 years now.The treatment during the six successful ITIepisodes reveals that the total dose of factor IXused was (mean and range) 182,000 IU (92,000-430,000). The duration of treatment was 25 days(15-39) and the daily dose per kg body weight170 IU (91-291).DiscussionIn Malmö, we have treated nine patients withsevere hemophilia B complicated by inhibitors ofwhom eight had a high-responding inhibitor.Tolerance was achieved in six patients after onetreatment attempt. In three patients (one ofwhom had a low-responding inhibitor), thetreatment failed using six treatment episodes. Inone of the successful patients, a relapse was seenafter six months. Thus, the Malmö ITI-modelgives a high response rate in the treatment ofhigh-responding factor IX inhibitor (6/8patients), although one relapse was seen. Thesefigures do not include two patients who wereunsuccessfully treated with a modified protocol. 14No serious complications were seen due to theproduct treatment during the treatment episodes,in those cases in which purified factor IX concentrateswere used and none of the patientsdeveloped the nephrotic syndrome. One patientreported previous allergic reactions. This patient,who did not respond to the protocol, was treatedlater on with a high-dose, long-term factor IXregimen and developed proteinuria. Althoughaware that our case series is small, we would liketo draw the following tentative conclusion. TheMalmö ITI-model gives a high-response rate inthe treatment of high-responding factor IXinhibitor patients. Only purified factor IX concentratesshould be used in order to avoid thromboemboliccomplications and the short treatmenttime (mean: 25 days) minimizes the risk ofdeveloping a nephrotic syndrome using theMalmö protocol. The Malmö model for ITI inhemophilia B may be considered as a startingpoint for a larger prospective study to evaluateand compare cost-effectiveness and the rate ofhaematologica vol. 88(supplement n. 12):september 2003
- Page 25 and 26: IV International Workshop on Immune
- Page 27 and 28: IV International Workshop on Immune
- Page 29 and 30: IV International Workshop on Immune
- Page 31 and 32: IV International Workshop on Immune
- Page 33 and 34: [Round Table on Immune Tolerance Tr
- Page 35 and 36: IV International Workshop on Immune
- Page 37 and 38: IV International Workshop on Immune
- Page 39 and 40: IV International Workshop on Immune
- Page 41 and 42: IV International Workshop on Immune
- Page 43 and 44: IV International Workshop on Immune
- Page 45 and 46: IV International Workshop on Immune
- Page 47 and 48: IV International Workshop on Immune
- Page 49 and 50: [Round Table on Immune Tolerance Tr
- Page 51 and 52: IV International Workshop on Immune
- Page 53 and 54: IV International Workshop on Immune
- Page 55 and 56: IV International Workshop on Immune
- Page 57 and 58: IV International Workshop on Immune
- Page 59 and 60: [Immunobiology of Tolerance Inducti
- Page 61 and 62: IV International Workshop on Immune
- Page 63 and 64: IV International Workshop on Immune
- Page 65 and 66: IV International Workshop on Immune
- Page 67 and 68: IV International Workshop on Immune
- Page 69 and 70: IV International Workshop on Immune
- Page 71 and 72: IV International Workshop on Immune
- Page 73 and 74: [New Aspects in Treatment of Hemoph
- Page 75: [New Aspects in Treatment of Hemoph
- Page 79 and 80: [New Aspects in Treatment of Hemoph
- Page 81 and 82: IV International Workshop on Immune
- Page 83 and 84: IV International Workshop on Immune
- Page 85 and 86: IV International Workshop on Immune
- Page 87 and 88: IV International Workshop on Immune
- Page 89 and 90: IV International Workshop on Immune
- Page 91 and 92: IV International Workshop on Immune
- Page 93 and 94: IV International Workshop on Immune
- Page 95 and 96: IV International Workshop on Immune
- Page 97 and 98: [Acquired Inhibitors in Non-Hemophi
- Page 99 and 100: IV International Workshop on Immune
- Page 101 and 102: IV International Workshop on Immune
- Page 103 and 104: IV International Workshop on Immune
- Page 105 and 106: IV International Workshop on Immune
- Page 107 and 108: IV International Workshop on Immune
- Page 109 and 110: IV International Workshop on Immune
- Page 111 and 112: IV International Workshop on Immune
- Page 113 and 114: IV International Workshop on Immune
- Page 115 and 116: [Gene Therapy]review paperThe host
- Page 117 and 118: IV International Workshop on Immune
- Page 119 and 120: [Gene Therapy]review paperGene ther
- Page 121 and 122: IV International Workshop on Immune
- Page 123 and 124: IV International Workshop on Immune
- Page 125 and 126: IV International Workshop on Immune
72E. BerntorpMaterials and MethodsStudy materialThe characteritics of the patients studied arelisted in Table 1. Nine patients with severe hemophiliaB (factor IX:C 300 394 4 >600 105 38 120 466 6 100 227 1 >300 58 1 429 1.69 27 3 29From the fourth day after the onset of treatment,gammaglobulin is given intravenously at dailydoses of 0.4 g/kg body weight for 5 days. Theinhibitor usually reappears after 5-6 days, andthe administration of factor concentrates mustbe intensified. For persistent inhibitors recombinantfactor VIIa (NovoSeven ® , Novo Nordisk) ispreferred for treatment of acute bleeds as acti-Figure 1. The Malmö model for Immune Tolerance Induction.haematologica vol. 88(supplement n. 12):september <strong>2003</strong>